株洲千金药业股份有限公司关于补血益母丸获批国家中药保护品种的公告

Core Viewpoint - The company, Zhuzhou Qianjin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its product, Bu Xue Yi Mu Wan, to be classified as the first secondary protected traditional Chinese medicine variety, enhancing its market competitiveness in postpartum recovery medication [1]. Group 1 - The approval of Bu Xue Yi Mu Wan as a secondary protected variety strengthens the company's intellectual property protection [1]. - Bu Xue Yi Mu Wan is recognized as a national basic drug, a Class A medical insurance variety, and an exclusive product, included in various clinical application guidelines and textbooks [1]. - The product is indicated for conditions related to postpartum abdominal pain due to deficiency of both qi and blood, as well as blood stasis [1]. Group 2 - The company anticipates that this approval will positively impact its production and operations [1]. - The sales performance of the drug may be influenced by national policies and market environment changes, indicating a level of uncertainty [2].